GEN-MKT-18-7897-A
May 25, 2018 | Blogs, Food / Beverage | 0 comments
As hospitals struggle with increasingly hard-to-treat antimicrobial resistance (ARM) bacterial infections, related deaths now exceed 700,000 per year globally and are predicted to reach 10 million per year by 2050. There’s no denying that these statistics are both shocking and concerning, as existing antibiotics are increasingly losing their effectiveness.
While researchers work relentlessly to discover new classes of powerful antibiotics that could someday help to address a looming public health crisis, measures are being taken to restrict the impact of drug-resistant infections. AMR occurs naturally over time and is a complex issue with a multitude of factors to consider when it comes to quantifying causes and managing prevention. However, antibiotic resistance is accelerated by the misuse and overuse of antibiotics, and the link between animal ingestion of antibiotics and increasing resistance in humans is widely acknowledged.
Preventing Drug Residues Hitchhiking into the Food ChainVeterinary drug residues are making their way into the food chain, and human consumption of meat, fish, and crops is contributing to ARM, as well as other health epidemics such as hypersensitivity reactions and carcinogenicity. The use of antibiotics for livestock greatly exceeds the use for humans, and it is estimated that animal ingestion of antibiotics accounts for approximately 70-80 percent of total consumption worldwide. This is having a direct impact on human antibiotic intake.
Fortunately, there is a higher awareness of potential risks surrounding the (improper) use of veterinary drugs, and many countries have enforced legislation to restrict the usage of these substances. Agriculture will always include a level of necessary use for good animal welfare or to prevent crop failure, but the intention is to reduce veterinary drug residue levels in food products.
Multiclass Veterinary Drug Residue and Antibiotic AnalysisDetecting trace quantities of veterinary drug residues can be challenging for labs because they are complex, containing actives from a variety of chemical classes, such as antibiotics, antiparasitics, and non-steroidal anti-inflammatory drugs. While there are several analytical approaches available, few come close to mass spectrometry in delivering a fast and highly selective routine screening method.
High-resolution accurate mass spec technology from SCIEX is proven to identify and quantify very low levels of multiclass antibiotics and hormone residues across a comprehensive range of food samples:
SCIEX combines best-in-class mass spec hardware, software and support services to bring you an extensive solution for faster and simpler multi-residue detection. If you want to simplify your veterinary drug residue and antibiotic analysis workflows with an accurate method that analyzes low levels of analytes within complex matrices, look no further than the cutting edge high-resolution accurate mass spec solutions from SCIEX.Access a range of informative videos, webinars, tech sheets and other useful resources >
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Posted by
You must be logged in to post a comment.
Share this post with your network